Emicizumab (Hemlibra)
Contents
Mechanism of action
A recombinant, humanized, bispecific monoclonal antibody that bridges activated factor IX and factor X to restore the function of missing activated factor VIII.
Diseases for which it is used
History of changes in FDA indication
- 11/16/2017: Approved "for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors."
- 10/4/2018: Approval expanded "for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (ages newborn and older) with hemophilia A (congenital factor VIII deficiency) with or without factor VIII (FVIII) inhibitors. (requirement for inhibitor to be present was removed)
Also known as
- Code name: ACE910
- Generic name: emicizumab-kxwh
- Brand name: Hemlibra
